


## Kylin Therapeutics

Kylin Therapeutics Inc. is developing a revolutionary RNA nanotechnology platform that gives clinicians and scientists the ability to selectively silence disease-causing genes related to cancer and viral diseases such as HIV.



Founded by West Lafayette, Ind.-based IN-vivo Ventures and Raleigh, N.C.-based Golden Pine Ventures, LLC, Kylin Therapeutics is focused on delivery and development of "pRNA," which is expected to exploit the enormous potential of RNA interference (RNAi).

RNAi was the subject of the 2006 Nobel Prize for Medicine and Physiology and is regarded as one of the most important therapeutic discoveries in decades.

RNAi is a natural gene "silencing" process within all cells. pRNA will exploit this process to selectively turn off genes responsible for illnesses such as cancer and infectious diseases. Harnessing the power of RNAi with pRNA holds enormous therapeutic potential.



In the past, the most significant challenges in developing RNA-based therapeutics have been delivery, stability and toxicity. Kylin has licensed Purdue University-patented pRNA technology solutions that overcome these hurdles.

In September 2007, Kylin Therapeutics signed a three-year collaboration with Fort Dodge Animal Health, a division of Wyeth. In exchange for research funding, Fort Dodge will receive an exclusive license to the pRNA/RNAi therapeutic compounds for the treatment of cancers in companion animals. Kylin will retain rights to the therapies for human use.

### Facts & Figures

<b>ESTABLISHED:</b>	July 2007 – Founded by IN-vivo Ventures, Golden Pine Ventures, and Peixuan Guo, Ph.D., a former Purdue University Professor of Molecular Virology and Biomedical Engineering.
<b>KEY PERSONNEL:</b>	J. Eric Davis, President and CEO; Joseph Trebley, Ph.D., Director of Technology Development; Peixuan Guo, Ph.D., Scientific Advisor
<b>EMPLOYEES:</b>	2
<b>CONTACT:</b>	Purdue Research Park, 3000 Kent Ave., West Lafayette, IN., 47906; (765) 412-6661; edavis@kylinththerapeutics.com; www.kylinththerapeutics.com



J. Eric Davis



Joseph Trebley